Search Results: (30 results)

This study will test how safe and effective the immunotherapy drug Olvi-Vec is, when it is followed by further chemotherapy and the drug bevacizumab in women diagnosed with platinum-resistant or refractory ovarian, fallopian tube or primary peritoneal cancer.

The study is designed to find the safest dose of a drug called TNG260, given along with a standard dose of the immunotherapy drug pembrolizumab, in people with advanced or metastatic solid tumors and have a STK11 genetic mutation.

The purpose of this study is to understand gastric (stomach) cancer risk among people with an inherited (germline) mutation in genes that are linked to an increased risk of certain cancers, including APC, ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), MUTYH, STK11, and other genes linked to increased cancer risk. 

This study will collect blood samples and MRI images from people at an increased risk of developing pancreatic cancer in order to improve early-stage detection methods in the future. 

This study will look at how often routine MRI scans detect abnormal findings in people with genetic mutations linked to hereditary cancer, specifically BRCA1, BRCA2, ATM, and PALB2, who are undergoing pancreatic cancer screening. Researchers aim to determine how frequent there are abnormal MRI and endoscopic ultrasound (EUS) results, as well as the occurrence of high-grade pancreatic precancerous lesions and pancreatic cancer. The study will also review the rate of procedures like biopsies and surgeries among participants. 

This research study is enrolling prostate cancer patients who plan to undergo surgery to have their prostate removed (radical prostatectomy) and whose cancer has one of the listed gene mutations: BRCA1, BRCA2, PALB2, RAD51B, RAD51C, RAD51D, RAD54L2, BARD1, FANCA or BRIP1.

This trial will study the safety, tolerability, and initial effectiveness of MOMA-313, a new type of targeted therapy, alone or in combination with the PARP inhibitor olaparib to treat people with advanced or metastatic cancers with certain types of mutations.

The study will determine whether the study medicine mevrometostat can delay or stop the growth of metastatic prostate cancer. Mevrometostat is thought to work by blocking the abnormal EZH2 activity in cells, which may help prevent or delay hormone therapy resistance and cancer growth and progression.

The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations. 

We are conducting a fully-online research study to learn more about how genes affect your risk of breast cancer. No office visit is required. Participants provide consent online, answer questions online about their health and medical history, and provide DNA via a saliva sample using a pre-paid mailer through the mail. In return for participation, study participants may receive information about their genetic ancestry for free.

PROMISE is a nationwide registry of prostate cancer patients with inherited mutations; screening approximately 5,000 participants with a prostate cancer diagnosis. The PROMISE team is studying how these mutations affect patient outcomes and hope to help patients learn more about their disease, the treatments that they may benefit most from, and any research studies that they may be eligible for.

The goal of this research study is to develop a new education program, called the ACT-Together intervention, to educate and support women who test positive for the BRCA1 or BRCA2 mutation on how they can reduce their risk of cancer in an online group setting.

Survey to share your views on a new method to track research specimens, like tissue or blood, you or your loved ones may have donated for science

This study is for people with advanced or metastatic breast cancer, have a BRCA1 or BRCA2 genetic mutation and were previously treated with a PARP inhibitor. The study will examine how effective  Olaparib in combination with Cediranib or Ceralasertib is in reducing the size of cancer and determining the length of time patients respond well to the treatment.

SHAREonline compares two brief educational interventions conducted by videoconference to learn if they help women age 19-49 manage sexual function changes after cancer treatment.

The primary goal of the study is to identify risk factors for developing secondary blood cancers and to understand how chemotherapy and PARP inhibitor exposure influence clonal changes in the blood that may predispose to later development of a blood cancer.

This study will look at the effectiveness of a new PARP inhibitor drug called AZD5305 in combination with different hormone therapies to treat metastatic prostate cancer, compared to the current standard treatment.

CAPS5 is a study looking at screening for early cancer in people with an elevated lifetime risk of developing pancreatic cancer. The goal is to study biomarkers derived from images and tissue samples (blood, pancreas fluid, duodenal fluid) for the early detection of pancreatic cancer and precancerous lesions.

This study seeks to explore the experiences of individuals with BRCA1 or BRCA2 mutations who were assigned male at birth. We aim to understand your journey to genetic testing and how you perceive and manage your cancer risks.

We are recruiting transgender, non-binary, and gender expansive people to join a research study. We want to learn how to better provide cancer prevention and gender affirming care. If you are at risk for cancer, we want to hear about your experiences talking to your doctor about gender-affirming hormones and cancer risk.

To explore patients' awareness of how medical treatments may affect fertility and identify helpful resources for future patients through a 10-15 minutes anonymous online survey. Enrollment ends on February 28,2025. Eligibility: Adults treated in the US for cancer, thalassemia, or sickle cell disease.

This study is looking at the safety of, and the immune system response to a vaccine in people diagnosed with pancreatic cancer. The vaccine will  be administered after chemotherapy. The vaccine will incorporate proteins that can trigger an immune response and will be given along with a drug called poly-ICLC which can also activate immune cells.

This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.

Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.

This study will explore how well cognitive training helps breast cancer survivors with their memory and thinking problems caused by cancer.

SOROCk [NRG-CC008] is a clinical trial studying if removal of just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes among women with an inherited BRCA1 mutation. The main benefit of removing only the fallopian tubes and not the ovaries is to prevent surgically-induced menopause. The study will also examine various patient-reported quality of life outcomes. Researchers believe that most ovarian cancers first begin in the fallopian tubes, suggesting that removing the fallopian tubes only may prevent the development of ovarian cancer. This concept has never been formally testing in a clinical trial.

The PATROL (Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease) study is for people at risk for prostate cancer because they carry one or more genes that are known or suspected to increase prostate cancer risk: BRCA2, HOXB13, ATM, BRCA1, MLH1, MSH2, MSH6, PALB2, PMS2, CHEK2, RAD51D, or TP53.

This study will interview palliative care patients and/or their adult family members (spouse, parents, children, siblings) who have been offered and involved in genetic testing or counseling related to the condition for which the patients are receiving palliative care.

This study explores how different levels of support systems influence coping strategies among LGBTQIA+ cancer patients, specifically patients who are over the age of 18, actively diagnosed with cancer, and reside in the United States.

Researchers are conducting a survey of cancer patients who were diagnosed with breast, colorectal, gastric or prostate cancer within the past twenty years. The aim is to gather information about their diagnosis, treatment, and personal experiences of battling cancer. The survey will collect data on the type of cancer, diagnosis, treatment plan, medications used, and personal stories throughout the journey to help gain a better understanding of the emotional and psychological impact of cancer on patients.

This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).